Page last updated: 2024-09-05

ly 353381 and fulvestrant

ly 353381 has been researched along with fulvestrant in 3 studies

Compound Research Comparison

Studies
(ly 353381)
Trials
(ly 353381)
Recent Studies (post-2010)
(ly 353381)
Studies
(fulvestrant)
Trials
(fulvestrant)
Recent Studies (post-2010) (fulvestrant)
7012152,7122071,196

Protein Interaction Comparison

ProteinTaxonomyly 353381 (IC50)fulvestrant (IC50)
Estrogen receptorHomo sapiens (human)0.0061
Estrogen receptorRattus norvegicus (Norway rat)0.0059
Progesterone receptorHomo sapiens (human)0.0002
Steroid hormone receptor ERR1Homo sapiens (human)0.002
Bifunctional epoxide hydrolase 2Homo sapiens (human)0.006
Estrogen receptor betaHomo sapiens (human)0.0104
Bile acid receptorHomo sapiens (human)0.79
NAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)2.6

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aparicio, A; Bonnefous, C; Brigham, D; Darimont, B; Douglas, K; Govek, S; Grillot, K; Hager, JH; Heyman, R; Joseph, JD; Julien, J; Kahraman, M; Kaufman, J; Lai, A; Lee, KJ; Lu, N; Moon, MJ; Nagasawa, J; Prudente, R; Qian, J; Rix, PJ; Sensintaffar, J; Shao, G; Smith, ND1
Chan, S1
Christensen, GL; Freddie, CT; Lykkesfeldt, AE1

Reviews

1 review(s) available for ly 353381 and fulvestrant

ArticleYear
A review of selective estrogen receptor modulators in the treatment of breast and endometrial cancer.
    Seminars in oncology, 2002, Volume: 29, Issue:3 Suppl 11

    Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Endometrial Neoplasms; Estradiol; Female; Fulvestrant; Humans; Piperidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Thiophenes

2002

Other Studies

2 other study(ies) available for ly 353381 and fulvestrant

ArticleYear
Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.
    Journal of medicinal chemistry, 2015, Jun-25, Volume: 58, Issue:12

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast; Breast Neoplasms; Cell Line, Tumor; Dogs; Drug Discovery; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Heterografts; Humans; Mice; Proteolysis; Rats; Selective Estrogen Receptor Modulators; Small Molecule Libraries; Tamoxifen

2015
A new MCF-7 breast cancer cell line resistant to the arzoxifene metabolite desmethylarzoxifene.
    Molecular and cellular endocrinology, 2004, May-31, Volume: 220, Issue:1-2

    Topics: Breast Neoplasms; Cathepsin D; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Fulvestrant; Histone Acetyltransferases; Humans; Nuclear Proteins; Nuclear Receptor Co-Repressor 1; Nuclear Receptor Coactivator 1; Piperidines; Proto-Oncogene Proteins c-bcl-2; Receptors, Progesterone; Repressor Proteins; RNA, Messenger; Tamoxifen; Thiophenes; Transcription Factors

2004